Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients

BACKGROUND: High-dose Interferon (HDI) therapy produces a clinical response and achieves relapse-free survival in 20-33% of patients with operable high risk or metastatic melanoma. However, patients may develop significant side effects frequently necessitating dose reduction or discontinuation of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Simons, Diana L, Lee, Gerald, Kirkwood, John M, Lee, Peter P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114759/
https://www.ncbi.nlm.nih.gov/pubmed/21545749
http://dx.doi.org/10.1186/1479-5876-9-52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114759/
https://www.ncbi.nlm.nih.gov/pubmed/21545749
http://dx.doi.org/10.1186/1479-5876-9-52

Ejemplares similares